1100P Open-label Non-Randomized Phase IB Study to Characterize the Safety, Tolerability and Recommended Dose of Tinostamustin in Combination with Nivolumab in Patients with Advanced Melanoma (ENIGMA)
ANNALS OF ONCOLOGY（2023）
Key words
Melanoma
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined